AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Corbus Pharmaceuticals Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

February 28, 2019

BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (NASDAQ: CRBP) and certain of its officers and directors violated federal securities laws.

On February 28, 2019, an article was published on Seeking Alpha titled, “Corbus Has Ties to Suspect Investors And A History Of Failed Clinical Trials for Lenabasum.”

Following the release of this article Corbus shares fell more than 14%.

If you have purchased or otherwise acquired Corbus securities and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorney Dan DeMaria at (888) 868-2385, by email at dan@blockesq.com, or by visiting http://shareholder.law/cases/?case=corbus.

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation’s largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP Dan DeMaria (617) 398-5660 phone 155 Federal Street, Suite 400 Boston, MA 02110 dan@blockesq.com

SOURCE Block & Leviton LLP